NCT02908906: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

NCT02908906
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Patients must have received prior treatment with an immune checkpoint inhibitor (i.e., pembrolizumab/Keytruda, atezolizumab/Tecentriq)
Exclusions: 
https://ClinicalTrials.gov/show/NCT02908906

Comments are closed.

Up ↑